Sugi Predict

Sugi Predict / Compounds / SCHEMBL700241

SCHEMBL700241

SCHEMBL700241

CC(C)(C)OC(=O)N1CCCC12CCNCC2

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 2/20 0.43
▸ GRIN2B Q13224 1/20 0.40
▸ GRIN2C Q14957 1/20 0.40
▸ SPR P35270 3/20 0.37
▸ NAMPT P43490 3/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ CNR2 P34972 2/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ RET P07949 1/20 0.34
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19582520 0.98 JAK3 (0.43) JAK3GRIN2BGRIN2CSPRNAMPT
SCHEMBL14762409 0.97 JAK3 (0.42) JAK3GRIN2BGRIN2CSPRNAMPT
Oxalic Acid SCHEMBL3984766 0.96 JAK3 (0.41) JAK3GRIN2BGRIN2CSPRNAMPT
SCHEMBL15286428 0.95 JAK3 (0.46) JAK3GRIN2BGRIN2CSPRNAMPT
Hydrochloric Acid SCHEMBL15288269 0.94 JAK3 (0.45) JAK3GRIN2BGRIN2CSPRNAMPT
SCHEMBL1771960 0.91 JAK3 (0.42) JAK3GRIN2BGRIN2CSPRNAMPT
SCHEMBL31450504 0.91 JAK3 (0.42) JAK3GRIN2BGRIN2CSPRNAMPT
SCHEMBL34473824 0.91 JAK3 (0.42) JAK3GRIN2BGRIN2CSPRNAMPT
SCHEMBL3706160 0.90 JAK3 (0.38) JAK3GRIN2BGRIN2CSPRUSP2
SCHEMBL14669188 0.89 JAK3 (0.45) JAK3GRIN2BGRIN2CSPRNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026101698-A1 HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF PROTAGONIST THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-20250346574-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-13 — — US disclosed
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 — — US disclosed
CN-118302418-B Aromatic heterocyclic compound and application thereof 中国科学院上海药物研究所 2025-05-02 — — CN disclosed
US-20250042862-A1 AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2025-02-06 — — US disclosed
EP-3634404-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2024-11-20 — — EP disclosed
WO-2024208187-A1 AZAARYL COMPOUND AND USE THEREOF AS LSD1 INHIBITOR 上海复星医药（集团）股份有限公司 2024-10-10 — — WO disclosed
EP-4431504-A1 AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) 2024-09-18 — — EP disclosed
US-20240300980-A1 HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT SHANGHAI KECHOW PHARMA, INC. (CN) 2024-09-12 — — US disclosed
WO-2024168004-A1 BIARYL AMIDE-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-08-15 — — WO disclosed
WO-2009027730-A1 QUINOLIN-4-ONE AND 4-OXODIHYDROCINNOLINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2009-03-05 — — WO disclosed
EP-1954698-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS Merck & Co., Inc. (US) 2008-08-13 — — EP disclosed
WO-2007061978-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
WO-2007061978-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
WO-2007061880-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
WO-2007061880-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
US-20070117824-A1 Spirocyclic compounds MERCK SHARP & DOHME LLC 2007-05-24 — — US disclosed
US-20070117824-A1 Spirocyclic compounds MERCK SHARP & DOHME LLC 2007-05-24 — — US disclosed
US-20070117824-A1 Spirocyclic compounds MERCK SHARP & DOHME LLC 2007-05-24 — — US disclosed
WO-2007025069-A2 DIAZASPIRODECANE OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300980-A1 HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT KRAS, NRAS, HRAS JAK3 1363/4885GRIN2B 4539/4885GRIN2C 4465/4885
US-20250042862-A1 AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF KDM1B, KDM1A, KDM3B JAK3 3941/4885GRIN2B 2089/4885GRIN2C 2063/4885
US-20250346574-A1 PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER RECQL, H1-5, H1-3 JAK3 3197/4885GRIN2B 2127/4885GRIN2C 2915/4885
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 JAK3 4297/4885GRIN2B 1568/4885GRIN2C 1849/4885
US-20070117824-A1 Spirocyclic compounds BRDT, TXNRD3, HDAC1 JAK3 3428/4885GRIN2B 2213/4885GRIN2C 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.